Targets › PTGES
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Jun 2027.
Terminal enzyme of the cyclooxygenase (COX)-2-mediated prostaglandin E2 (PGE2) biosynthetic pathway. Catalyzes the glutathione-dependent oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) in response to inflammatory stimuli. (UniProt, O14684)
Open in Phaseline: the race on PTGES, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gesynta Pharma | Vipoglanstat mPGES-1 (microsomal prostaglandin E synthase-1) inhibitor | PTGES | Phase 2 | Endometriosis | Jun 2027 |
Endometriosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.